High Ranking
- This study aimed to describe the results of paired tumor and germline DNA testing of the MMR genes for individuals with tumors demonstrating IL-PMS2 at one laboratory.
- In this cohort, 67% of tumors demonstrating IL-PMS2 were explained by germline PMS2 or MLH1 mutations, MLH1 promoter hypermethylation, or MMR deficiency due to one somatic MLH1 mutation in the presence of CN-LOH.
- These data support the importance of adding comprehensive paired tumor and germline MMR gene analyses to the Lynch syndrome testing algorithm which will allow clinicians to further distinguish between sporadic tumors and Lynch syndrome.